Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D

Part of paid clinical trials in Idaho Falls, Idaho.

Sponsor
Carla Greenbaum, MD
Study ID
NCT03632759
Phase
EARLY_PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide — DRUG
    Participants will receive subcutaneous (SC) liraglutide for 8 weeks
  • Golimumab — DRUG
    Participants will receive subcutaneous (SC) golimumab for 8 weeks

Study Details

The purpose of this study is to determine whether 8 weeks of Liraglutide or Golimumab can transiently improve beta cell function in patients with longstanding Type 1 diabetes (T1D) who secrete proinsulin and little/no C-peptide.

Key Dates

Start date
Aug 15, 2018
Status verified
Jan 2022
Primary completion
Nov 9, 2021
Completion
Nov 9, 2021

Study Design

Enrollment
16 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Liraglutide
    Participants will receive subcutaneous (SC) liraglutide for 8 weeks
  • Experimental: Golimumab
    Participants will receive subcutaneous (SC) golimumab for 8 weeks

Primary Outcome Measure

Proportion of individuals with peak MMTT stimulated C-peptide >0.017 pmol/mL. [ Time Frame: 0-to-8 weeks ]

Locations (2)

FacilityCityStateZIPSite coordinators
Rocky Mountain Diabetes and Osteoporosis CenterIdaho FallsIdaho83404-
Benaroya Research InstituteSeattleWashington98101-

Find similar trials in Idaho Falls, ID

By condition
Type 1 diabetes
By specialty
Endocrinology
By research site
Rocky Mountain Diabetes and Osteoporosis Center· Idaho Falls, IDBenaroya Research Institute· Seattle, WA

Related Studies